Gespeichert in:
| Beteilige Person: | |
|---|---|
| Format: | Buch |
| Sprache: | Deutsch |
| Veröffentlicht: |
Stuttgart
Thieme
[2018]
|
| Schriftenreihe: | Case report
10. Jahrgang, Heft 12 (September 2018) |
| Umfang: | 15 Seiten Illustrationen, Diagramme |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV045479959 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t| | ||
| 008 | 190220s2018 xx a||| |||| 00||| ger d | ||
| 035 | |a (OCoLC)1060992567 | ||
| 035 | |a (DE-599)HBZHT019821077 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a ger | |
| 049 | |a DE-19 | ||
| 245 | 1 | 0 | |a Tofacitinib (Xeljanz) |b der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa |c Herausgeber Prof. Dr. Markus Neurath |
| 264 | 1 | |a Stuttgart |b Thieme |c [2018] | |
| 300 | |a 15 Seiten |b Illustrationen, Diagramme | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Case report |v 10. Jahrgang, Heft 12 (September 2018) | |
| 700 | 1 | |a Neurath, Markus |d 1965- |0 (DE-588)115599444 |4 edt |4 aut | |
| 772 | 0 | 8 | |i Beigelegt in |t Zeitschrift für Gastroenterologie |g 56. Jahrgang (2018) |
| 830 | 0 | |a Case report |v 10. Jahrgang, Heft 12 (September 2018) |w (DE-604)BV044781118 |9 10,12 | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-030865061 | |
Datensatz im Suchindex
| _version_ | 1818985011978698752 |
|---|---|
| any_adam_object | |
| author | Neurath, Markus 1965- |
| author2 | Neurath, Markus 1965- |
| author2_role | edt |
| author2_variant | m n mn |
| author_GND | (DE-588)115599444 |
| author_facet | Neurath, Markus 1965- Neurath, Markus 1965- |
| author_role | aut |
| author_sort | Neurath, Markus 1965- |
| author_variant | m n mn |
| building | Verbundindex |
| bvnumber | BV045479959 |
| ctrlnum | (OCoLC)1060992567 (DE-599)HBZHT019821077 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01017nam a2200277 cb4500</leader><controlfield tag="001">BV045479959</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">190220s2018 xx a||| |||| 00||| ger d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1060992567</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)HBZHT019821077</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Tofacitinib (Xeljanz)</subfield><subfield code="b">der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa</subfield><subfield code="c">Herausgeber Prof. Dr. Markus Neurath</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Stuttgart</subfield><subfield code="b">Thieme</subfield><subfield code="c">[2018]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Case report</subfield><subfield code="v">10. Jahrgang, Heft 12 (September 2018)</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Neurath, Markus</subfield><subfield code="d">1965-</subfield><subfield code="0">(DE-588)115599444</subfield><subfield code="4">edt</subfield><subfield code="4">aut</subfield></datafield><datafield tag="772" ind1="0" ind2="8"><subfield code="i">Beigelegt in</subfield><subfield code="t">Zeitschrift für Gastroenterologie</subfield><subfield code="g">56. Jahrgang (2018)</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Case report</subfield><subfield code="v">10. Jahrgang, Heft 12 (September 2018)</subfield><subfield code="w">(DE-604)BV044781118</subfield><subfield code="9">10,12</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030865061</subfield></datafield></record></collection> |
| id | DE-604.BV045479959 |
| illustrated | Illustrated |
| indexdate | 2024-12-20T18:28:07Z |
| institution | BVB |
| language | German |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030865061 |
| oclc_num | 1060992567 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | 15 Seiten Illustrationen, Diagramme |
| publishDate | 2018 |
| publishDateSearch | 2018 |
| publishDateSort | 2018 |
| publisher | Thieme |
| record_format | marc |
| series | Case report |
| series2 | Case report |
| spelling | Tofacitinib (Xeljanz) der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa Herausgeber Prof. Dr. Markus Neurath Stuttgart Thieme [2018] 15 Seiten Illustrationen, Diagramme txt rdacontent n rdamedia nc rdacarrier Case report 10. Jahrgang, Heft 12 (September 2018) Neurath, Markus 1965- (DE-588)115599444 edt aut Beigelegt in Zeitschrift für Gastroenterologie 56. Jahrgang (2018) Case report 10. Jahrgang, Heft 12 (September 2018) (DE-604)BV044781118 10,12 |
| spellingShingle | Neurath, Markus 1965- Tofacitinib (Xeljanz) der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa Case report |
| title | Tofacitinib (Xeljanz) der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa |
| title_auth | Tofacitinib (Xeljanz) der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa |
| title_exact_search | Tofacitinib (Xeljanz) der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa |
| title_full | Tofacitinib (Xeljanz) der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa Herausgeber Prof. Dr. Markus Neurath |
| title_fullStr | Tofacitinib (Xeljanz) der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa Herausgeber Prof. Dr. Markus Neurath |
| title_full_unstemmed | Tofacitinib (Xeljanz) der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa Herausgeber Prof. Dr. Markus Neurath |
| title_short | Tofacitinib (Xeljanz) |
| title_sort | tofacitinib xeljanz der erste januskinase inhibitor in der therapie von colitis ulcerosa |
| title_sub | der erste Januskinase-Inhibitor in der Therapie von Colitis ulcerosa |
| volume_link | (DE-604)BV044781118 |
| work_keys_str_mv | AT neurathmarkus tofacitinibxeljanzdererstejanuskinaseinhibitorindertherapievoncolitisulcerosa |